1-10 of 10
James M. Ford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The New NCI Precision Medicine Trials

Lyndsay N. Harris, Charles D. Blanke, Harry P. Erba, James M. Ford, Robert J. Gray, Michael L. LeBlanc, Siwen Hu-Lieskovan, Mark R. Litzow, Selina M. Luger, Funda Meric-Bernstam, Peter J. O'Dwyer, Megan K.D. Othus, Katerina Politi, Lois E. Shepherd, Carmen J. Allegra, Helen X. Chen, S. Percy Ivy, Larissa A. Korde, Richard F. Little, Lisa M. McShane, Jeffrey A. Moscow, David R. Patton, Magdalena Thurin, Laura M. Yee, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4728–4732.
https://doi.org/10.1158/1078-0432.CCR-23-0917
Published: 01 December 2023
View article titled, The New NCI Precision Medicine Trials
Open the PDF for The New NCI Precision Medicine Trials in another window
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

Melinda L. Telli, Charles Chu, Sunil S. Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia Kaklamani, William Gradishar, Vered Stearns, Roisin M. Connolly, James M. Ford, Joshua J. Gruber, Sylvia Adams, Judy Garber, Nadine Tung, Chris Neff, Ryan Bernhisel, Kirsten M. Timms, Andrea L. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2704–2710.
https://doi.org/10.1158/1078-0432.CCR-19-0664
Published: 01 June 2020
View article titled, Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <em>BRCA1/2</em> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Open the PDF for Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <em>BRCA1/2</em> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis in another window
Journal Articles

High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients

Justin Chen, Maria K. Haanpää, Joshua J. Gruber, Natalie Jäger, James M. Ford, Michael P. Snyder
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5301–5314.
https://doi.org/10.1158/1078-0432.CCR-18-2423
Published: 03 September 2019
View article titled, High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Open the PDF for High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Anosheh Afghahi, Natasha Purington, Summer S. Han, Manisha Desai, Emma Pierson, Maya B. Mathur, Tina Seto, Caroline A. Thompson, Joseph Rigdon, Melinda L. Telli, Sunil S. Badve, Christina N. Curtis, Robert B. West, Kathleen Horst, Scarlett L. Gomez, James M. Ford, George W. Sledge, Allison W. Kurian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2851–2858.
https://doi.org/10.1158/1078-0432.CCR-17-1323
Published: 14 June 2018
View article titled, Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
Open the PDF for Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

Anosheh Afghahi, Kirsten M. Timms, Shaveta Vinayak, Kristin C. Jensen, Allison W. Kurian, Robert W. Carlson, Pei-Jen Chang, Elizabeth Schackmann, Anne-Renee Hartman, James M. Ford, Melinda L. Telli
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3365–3370.
https://doi.org/10.1158/1078-0432.CCR-16-2174
Published: 02 July 2017
View article titled, Tumor <em>BRCA1</em> Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
Open the PDF for Tumor <em>BRCA1</em> Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance in another window
Includes: Supplementary data
Journal Articles

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli, Kirsten M. Timms, Julia Reid, Bryan Hennessy, Gordon B. Mills, Kristin C. Jensen, Zoltan Szallasi, William T. Barry, Eric P. Winer, Nadine M. Tung, Steven J. Isakoff, Paula D. Ryan, April Greene-Colozzi, Alexander Gutin, Zaina Sangale, Diana Iliev, Chris Neff, Victor Abkevich, Joshua T. Jones, Jerry S. Lanchbury, Anne-Renee Hartman, Judy E. Garber, James M. Ford, Daniel P. Silver, Andrea L. Richardson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (15): 3764–3773.
https://doi.org/10.1158/1078-0432.CCR-15-2477
Published: 31 July 2016
View article titled, Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Open the PDF for Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR07: Precision genomic medicine improves clinical outcomes in advanced cancer patients

Lincoln D. Nadauld, Burke Van Norman, Gail Fulde, David newman, Allison Butler, Brian Tudor, Heather Gilbert, Karen Lin, Gary Stone, Anish Konde, Iva Petrovchich, James M. Ford, Derrick Haslem
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1_Supplement): PR07.
https://doi.org/10.1158/1557-3265.PMSCLINGEN15-PR07
Published: 03 January 2016
View article titled, Abstract PR07: Precision genomic medicine improves clinical outcomes in advanced cancer patients
Journal Articles

Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer

Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Dent, Daniel P. Silver, George W. Sledge, Lisa A. Carey
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4702–4710.
https://doi.org/10.1158/1078-0432.CCR-10-0939
Published: 29 September 2010
View article titled, Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Open the PDF for Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer in another window
Journal Articles

Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management

Gianpaolo Suriano, Sandie Yew, Paulo Ferreira, Janine Senz, Pardeep Kaurah, James M. Ford, Teri A. Longacre, Jeffrey A. Norton, Nicki Chun, Sean Young, Maria J. Oliveira, Barbara MacGillivray, Arundhati Rao, Dawn Sears, Charles E. Jackson, Jeff Boyd, Cindy Yee, Carolyn Deters, G. Shashidhar Pai, Lyn S. Hammond, Bobbi J. McGivern, Diane Medgyesy, Denise Sartz, Banu Arun, Brant K. Oelschlager, Mellisa P. Upton, Whitney Neufeld-Kaiser, Orlando E. Silva, Talia R. Donenberg, David A. Kooby, Shobha Sharma, Björn-Anders Jonsson, Henrik Gronberg, Steve Gallinger, Raquel Seruca, Henry Lynch, David G. Huntsman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5401–5409.
https://doi.org/10.1158/1078-0432.CCR-05-0247
Published: 01 August 2005
View article titled, Characterization of a Recurrent Germ Line Mutation of the <em>E-Cadherin</em> Gene: Implications for Genetic Testing and Clinical Management
Open the PDF for Characterization of a Recurrent Germ Line Mutation of the <em>E-Cadherin</em> Gene: Implications for Genetic Testing and Clinical Management in another window